EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study

Michael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, Klaus-Friedrich Bodmann

GMS Infectious Diseases; 8:Doc25 · 15.12.2020 · 8 · Doc25-Doc25

DOI: 10.3205/id000069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GMS Infectious Diseases; 8:Doc25, erschienen am 15.12.2020. Verfasst von Michael Wilke und 3 weiteren Autor:innen. Beteiligte Einrichtung: inspiring-health GmbH, Munich, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sepsis and bloodstream infections pose severe challenges in intensive care. Early reliable diagnosis is the key to successful therapy. The objective of the study presented here was to investigate the clinical and economical effects of the new PhenoTM BC test, which allows bacteria identification (ID) and antimicrobial susceptibility testing (AST) in approximately 7 hours after a blood culture becomes positive (BC+).

Methods

Historically controlled interventional study. Population: patients with BC+ and ICU admission. Inadequate initial antimicrobial therapy (IAT) is need of therapy change based on result. Prospectively the new test was used in addition. Primary endpoint: time-to-result in hours. Contribution margin (CM) i.e. revenue – costs was computed. All patients formed the intention-to-treat population (ITT). Patients with complete cost data formed the modified ITT group (mITT). CM results were calculated for mITT and PP. Further analyses: length-of-stay (LOS) and mortality.

Results

223 historical and 200 prospective patients were included. Time to result (ITT) was shortened by 51.1 hours (83 vs. 31.9; p

Schlagwörter

Stichwörter der Autor:innen

ASTantimicrobial stewardshipantimicrobial susceptibility testingbloodstream infectionscostshealth economicsrapid bacteria identificationsepsis

Autor:innen und Institutionen

  • inspiring-health GmbH, Munich, Germany.
  • Kliniken Nordoberpfalz AG, Klinikum Weiden, Germany.

Zitieren

APA

Wilke, M., Heinlein, W., Stiefenhofer, L., & Bodmann, K. F. (2020). Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study. GMS Infectious Diseases; 8:Doc25, 8, Doc25-Doc25. https://doi.org/10.3205/id000069

Vancouver

Wilke M, Heinlein W, Stiefenhofer L, Bodmann KF. Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study. GMS Infectious Diseases; 8:Doc25. 2020;8:Doc25-Doc25. doi:10.3205/id000069

BibTeX
@article{Wilke2020,
  author = {Wilke, Michael and Heinlein, Wolfgang and Stiefenhofer, Luis and Bodmann, Klaus-Friedrich},
  title = {Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON study},
  journal = {GMS Infectious Diseases; 8:Doc25},
  year = {2020},
  volume = {8},
  pages = {Doc25--Doc25},
  doi = {10.3205/id000069}
}
Kostenlos starten →